Age-and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 29, Issue 10, 2013, Pages 926-930

  Panidis, Dimitrios ^a   Tziomalos, Konstantinos ^b   MacUt, Djuro ^c   Kandaraki, Eleni A ^a   Tsourdi, Elena A ^a   Papadakis, Efstathios ^a   Katsikis, Ilias ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Age; Body mass index; Metabolic syndrome; Obesity; Polycystic ovary syndrome

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PREVALENCE; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84883570460     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.819079     Document Type: Article

References (30)

1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31.
2. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35.
4. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:1311-17.
5. Cussons AJ, Watts GF, Burke V, et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-8.
6. Shroff R, Syrop CH, Davis W, et al. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389-95.
7. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-63.
8. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010;26:713-19.
9. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.
10. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term followup focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-13.
11. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J.Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-8.
12. Panidis D, Tziomalos K, Macut D, et al. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. Fertil Steril 2012;97:494-500.
13. Panidis D, Macut D, Tziomalos K, et al. Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013;78:586-92.
14. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
17. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
18. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology task force consensus group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.
19. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
20. Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238-43.
21. Macut D, Damjanovic S, Panidis D, et al. Oxidised low-density lipoprotein concentration-early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 2006; 155:131-6.
22. Carter GD, Holland SM, Alaghband-Zadeh J, et al. Investigation of hirsutism: testosterone is not enough. Ann Clin Biochem 1983;20: 262-3.
23. Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-29.
24. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85: 2402-10.
25. Ferrannini E, Vichi S, Beck-Nielsen H, et al. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-53.
26. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005;62:644-9.
27. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53.
28. Spencer JB, Klein M, Kumar A, Azziz R. The ageassociated decline of androgens in reproductive age and menopausal Black and White women. J Clin Endocrinol Metab 2007;92:4730-3.
29. Attaoua R, Ait El Mkadem S, Radian S, et al. FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 2008;373:230-4.
30. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.